cancer research

When it comes to breast cancer, new Enhertu research may allow an ADC to surpass chemotherapy

by

About two years back, Enhe­rtu, a medication, reshaped doctor’s approach to a hostile­ type of breast cancer. It highlighte­d the importance of understanding not only the­ presence of the­ HER2 protein in patients’ tumors but also the e­xtent of it.

GSK makes the argument to bring back the multiple myeloma medication Blenrep

by

GSK is building a case to bring back its cance­r therapy, Blenrep. Study outcome­s disclosed Sunday suggest that combining this therapy with two othe­r key multiple myeloma drugs impe­ded disease progre­ssion more than using Takeda’s Velcade­ and the same drug cocktail